Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Yale, J.‐F.; Bakris, G.; Cariou, Bertrand; Nieto Guevara, Javier; David‐Neto, Elias; K. Yue, Dennis; Wajs, Ewa; Figueroa, K.; Jiang, Joel; Law, Ga‐Lai; Usiskin, Keith; Meininger, Gary; behalf of the DIA3004 Study Group, on

doi:10.1111/dom.12348

Public

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Published in Diabetes Obesity and Metabolism • Jun 25, 2014

Authors:

J.‐F. Yale

G. Bakris

Bertrand Cariou

Abstract

AIM: This study evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and within a subset of Stage 3 chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] ≥ 30 and <50 ml/min/1.73 m(2)). ME...

Subject

Canagliflozin

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!